Immune Profiles Study - A longitudinal, observational study of patients with newly diagnosed glioma
Summary
This project will use cutting-edge epigenomic science to develop and validate a new generation of immune biomarkers to improve glioma survival prognostication and will provide clinically applicable tools to identify tumor isocitrate dehydrogenase (IDH) status prior to surgical intervention and evaluate the effects of radiation and immunotherapy.
Gliomas are a heterogeneous group of tumors with diverse clinical outcomes. While IDH mutation and other genetic features of glioma have changed the landscape of diagnosis and prognosis for lower-grade glioma, these same markers do not explain heterogeneity in treatment response and survival for glioblastoma (GBM). Individual immune factors may play a role in glioma outcomes. To address this, we have pioneered immunomethylomics, an approach that defines and quantitates an extended library of immune cell populations (e.g., naïve and memory CD4, CD8 T-cells, and B cells, NK cells, monocytes, neutrophils) and aberrant myeloid-derived suppressor cells (MDSCs) from fresh or frozen peripheral whole blood. Immunomethylomics is a powerful methodology based on patterns of DNA methylation in the immune cell genomes. We will use immunomethylomics to address high-priority, and yet unresolved, clinical problems in GBM patient management.
- Blood Sample Donation. Study participants will be asked to give a blood sample roughly every two months during the course of their treatment. The sample usually can be done as part of routine lab work and may be drawn either at UCSF or a local lab. For blood draws at a local lab, we will mail you a blood collection kit. Each blood sample collected is about three tablespoons.
- Short Survey. We will also ask you about your background and personal medical history and around the time of each blood draw, we will ask you about your current medications.
- Voluntary Participation. Participation in this study is completely voluntary and will not influence your treatment or medical record. All of the information collected will be confidential, and neither your name nor any other identifying information will appear in any report from the study.
Study Coordinator(s)
|
|
Laboratory Manager
- Written informed consent.
- At least 18 years of age.
- Suspected new primary glioma diagnosis.
- Surgery for biopsy or resection planned at UCSF.
- Patients with a diminished capacity to consent for themselves.
- Patients who do not speak English.
- Patients who do not reside in the United States.
- Bracci PM, Rice T, Hansen HM, Francis SS, Lee S, McCoy LS, Shrestha PP, Warrier G, Clarke JL, Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Pre-surgery immune profiles of adult glioma patients. J Neurooncol. 2022;159(1):103-15. DOI: 10.1007/s11060-022-04047-y. Pubmed PMID:35716311; PMCID:PMC9325836.
- Tang E, Wiencke JK, Warrier G, Hansen H, McCoy L, Rice T, Bracci PM, Wrensch M, Taylor JW, Clarke JL, Koestler DC, Salas LA, Christensen BC, Kelsey KT, Molinaro AM. Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker. Clin Epigenetics. 2022;14(1):136. DOI:10.1186/s13148-022-01352-1. Pubmed PMID:36307860; PMCID:PMC9617416.
- Wiencke JK, Molinaro AM, Warrier G, Rice T, Clarke J, Taylor JW, Wrensch M, Hansen H, McCoy L, Tang E, Tamaki SJ, Tamaki CM, Nissen E, Bracci P, Salas LA, Koestler DC, Christensen BC, Zhang Z, Kelsey KT. DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival. Nat Commun. 2022;13(1):5505. DOI:10.1038/s41467-022-33215-x. Pubmed PMID:36127421; PMCID:PMC9486797.
- Molinaro AM, Wiencke JK, Warrier G, Koestler DC, Chunduru P, Lee JY, Hansen HM, Lee S, Anguiano J, Rice T, Bracci PM, McCoy L, Salas LA, Christensen BC, Wrensch M, Kelsey KT, Taylor JW, Clarke JL. Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. J Natl Cancer Inst. 2022;114(3):446-57. DOI:10.1093/jnci/djab195. Pubmed PMID:34597382; PMCID:PMC8902347.
